Brain

Relief Mental Health Sheds Light on Innovative Treatments During Mental Health Awareness Month

Retrieved on: 
Wednesday, May 1, 2024
Mental Health, Alternative Medicine, Other Health, Health, Pharmaceutical, FDA, Brain, Hope, Tic disorder, Mental Health Awareness Month, DSM-IV codes, OCD, PTSD, Field line, MD, Depression, Grammatical mood, Ketamine, Mental health, Transcranial magnetic stimulation, Anxiety, TMS, Pharmaceutical industry

As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.

Key Points: 
  • As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.
  • "TMS, Spravato, and IV ketamine represent a new frontier in mental health treatment, offering relief to those who have struggled with traditional therapies,” said Teresa Poprawski, MD , a neuropsychiatrist and chief medical officer at Relief Mental Health.
  • In honor of Mental Health Month and to help educate the public on the benefits of TMS specifically, Relief Mental Health is hosting an Instagram Live event on Friday, May 17, at 10 a.m. central time.
  • For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email [email protected] or visit reliefmh.com .

Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

Retrieved on: 
Wednesday, May 1, 2024
Research, Infectious Diseases, Clinical Trials, Health Technology, Philanthropy, General Health, Pharmaceutical, Health, Science, Oncology, Brain, MCI, Cancer, IP, Blood, Magnetic resonance, Immunotherapy, Pharmacotherapy, Speech, Digital, Therapy, Moa, Patient, Physician, Movement, Biomarker, Immune system, Mechanism, Sensory deprivation, Medical imaging

Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.

Key Points: 
  • Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.
  • The digital molecules are designed for hybrid drug experiences.
  • Remepy’s innovative approach creates a new market for hybrid medications, and a whole new world of data and IP assets for pharmaceutical companies.
  • Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments.

Axion BioSystems Adds Affordable Maestro Volt™ to its Industry-Leading MEA System Lineup

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Neurology, Health Technology, Other Science, Research, Software, Science, Brain, Axion, Maestro, MEA, 3D, Glioblastoma, Disease, BioSystems, Epilepsy, Regenerative medicine, Multimedia, Neuron, 2D, Medicine, Pharmaceutical industry

Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets.

Key Points: 
  • Axion BioSystems today announced the launch of the new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets.
  • Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications.
  • The new device expands Axion’s flagship Maestro product line and promises to drive scientific discovery by making MEA technology more broadly available.
  • View the full release here: https://www.businesswire.com/news/home/20240430599407/en/
    Maestro Volt: The affordable MEA system for every lab.

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
Monday, April 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .

Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial

Retrieved on: 
Monday, April 29, 2024
Health, Other Science, Clinical Trials, Research, Science, Optical, Biotechnology, AMD, Brain, University, Iron, Cell, Risk, Publication, Iron overload, Central nervous system, Inflammasome, K8, Disease, Nervous system, Patient, Eye, Multiple sclerosis, DSM-IV codes, ALS, Multimedia, Atrophy, Reactive oxygen species, Therapy, Ophthalmology, Science and nature, Pharmaceutical industry

Inflammasome Therapeutics ( https://www.inflam.com ), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a first-in-class clinical trial for dry AMD.

Key Points: 
  • Inflammasome Therapeutics ( https://www.inflam.com ), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a first-in-class clinical trial for dry AMD.
  • “This marks the second trial underway with our Kamuvudines in ophthalmology,” said Dr. Paul Ashton, President and CEO of Inflammasome Therapeutics, developers of both the compounds and delivery systems for administration.
  • There are 38 other interventional clinical trials for GA registered in clinicaltrials.gov., almost all of which target individual toxic substances, but not the underlying cause of the atrophy, inflammasome activation.
  • Inflammasome Therapeutics is expected to begin clinical trials in some of these diseases soon as well,” he affirmed.

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

Retrieved on: 
Tuesday, April 30, 2024
Research, Medical Devices, Surgery, Infectious Diseases, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Pain, Brain, Rat, Liposome, Post-traumatic stress disorder, Hematology, Animal, Bupivacaine, Human, IND, CNS, MTD, Pain management, Maxima and minima, Central nervous system, Index, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.
  • Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
  • Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain.
  • The study was designed to determine the MTD of free bupivacaine, Probudur, and Probudur plus free bupivacaine when administered as a single subcutaneous injection to the wound.

ASHA Shares New Resources on Developmental Milestones With Families This National Speech-Language-Hearing Month

Retrieved on: 
Tuesday, April 30, 2024
Brain, American Speech–Language–Hearing Association, Language, Hearing, Audiology, Thought, Disorder, Communication, Parent, Life, Speech, Marie Cassidy, Family, ASHA, Caregiver, Child, Toy

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- A child's first word or their first time eating from a spoon are events that most parents and caregivers eagerly anticipate—just two of the many developmental milestones that babies are expected to meet in their first year of life. But knowing exactly when specific milestones should occur, and whether delays in achieving them are cause for concern, can be challenging for families. To help them, the American Speech-Language-Hearing Association (ASHA) is providing a series of new resources—just in time for National Speech-Language-Hearing Month, which is recognized each May in the United States.

Key Points: 
  • But knowing exactly when specific milestones should occur, and whether delays in achieving them are cause for concern, can be challenging for families.
  • Milestones can also serve to alert families about a potential developmental delay or disorder in their child.
  • Last fall, ASHA issued new communication milestones for children ages birth to 5 years, and new feeding and swallowing milestones for children ages birth to 3 years.
  • For more information on ASHA's developmental milestones, and tips about what can be done at home to encourage a child's development, visit ASHA's website .

Two Canadian teams awarded new funding to study mental illness in youth with rheumatic diseases

Retrieved on: 
Thursday, April 11, 2024
University, Rheumatology, Arthritis, Partnership, Research, Mental health, Brain, Rheumatism, Child, Lupus, Juvenile idiopathic arthritis, Prevalence, Nursing

This year’s awardees are Roberta Berard, from the London Health Science Centre and Mark Ferro, of the University of Waterloo.

Key Points: 
  • This year’s awardees are Roberta Berard, from the London Health Science Centre and Mark Ferro, of the University of Waterloo.
  • Both teams are advancing efforts to better prevent, diagnose, and treat mental illnesses in children and young adults with rheumatic diseases such as juvenile idiopathic arthritis and lupus.
  • These conditions affect approximately 24,000 children and youth across Canada, impacting their daily lives and overall well-being.
  • "Our partnership reaffirms our dedication to supporting groundbreaking research that has the capacity to profoundly improve the lives of Canadian youth navigating mental health challenges."

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Retrieved on: 
Thursday, April 11, 2024
Janus, Autoantibody, Glomerulonephritis, Brain, Blood, Inflammation, EDT, Skin, Survival, Pathology, Lupus, Joint, CD19, Autoimmune disease, Patient, Acquisition, DSM-IV codes, Immune system, Therapy, Vaccine

SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.

Key Points: 
  • In support of the acquisition, Eliem has entered into a securities purchase agreement for a $120 million private placement of common stock with a syndicate of new and existing institutional life science investors including RA Capital Management, Deep Track Capital, Boxer Capital, Janus Henderson Investors, Pontifax and Samsara Biocapital.
  • The private placement is expected to close concurrently with the closing of the acquisition.
  • Immediately following the closing of the acquisition and the private placement, the total cash and cash equivalents of the combined company are expected to be approximately $210 million.
  • The acquisition and private placement are expected to close in the middle of 2024, subject to approval by Eliem’s stockholders and other customary closing conditions.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Retrieved on: 
Wednesday, April 10, 2024
Molecular Therapy, Brain, Euronext Growth, Therapy, TALEN, Research, DSM-IV codes

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage.

Key Points: 
  • NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage.
  • This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain.